Search research articles
Contact Us
Filters
Showing results (421-430 of 457) with videos related to
Page
of 46
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2011
Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion
Yirong Li, Martin Ligr, James P McCarron, et al.
European Urology
|
June 27, 2015
Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes
Xiaosong Meng, Andrew B Rosenkrantz, Neil Mendhiratta, et al.
Pathology, Research and Practice
|
May 7, 2022
Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations
Lei Zhang, Xiaoyan Liu, Rong Xia, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 20, 2018
Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis
Mao-Wen Weng, Hyun-Wook Lee, Sung-Hyun Park, et al.
Radiation Oncology (London, England)
|
March 4, 2024
High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy
Jonathan W Lischalk, Astrid Sanchez, Vianca F Santos, et al.
Urology
|
December 11, 2003
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer
Yoshio Naya, Herbert A Fritsche, Carol D Cheli, et al.
Urology
|
October 18, 2002
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter
Wolfgang Horninger, Carol D Cheli, Richard J Babaian, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 28, 2017
Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202
Amin J Mirhadi, Qiang Zhang, Gerald E Hanks, et al.
The New England Journal of Medicine
|
March 25, 2026
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Ann Marie Navar, Elina Mikhailova, Alberico L Catapano, et al.
Urology
|
October 18, 2002
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
Yoshio Naya, Thomas A Stamey, Carol D Cheli, et al.
Page
of 46
Search research articles
Search
Showing results (421-430 of 457) with videos related to
Sort By:
Page
of 46
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 25, 2011
Natura-alpha targets forkhead box m1 and inhibits androgen-dependent and -independent prostate cancer growth and invasion
Yirong Li, Martin Ligr, James P McCarron, et al.
European Urology
|
June 27, 2015
Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes
Xiaosong Meng, Andrew B Rosenkrantz, Neil Mendhiratta, et al.
Pathology, Research and Practice
|
May 7, 2022
Comparison of the clinicopathologic features of prostate cancer in US and Chinese populations
Lei Zhang, Xiaoyan Liu, Rong Xia, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 20, 2018
Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis
Mao-Wen Weng, Hyun-Wook Lee, Sung-Hyun Park, et al.
Radiation Oncology (London, England)
|
March 4, 2024
High-volume prostate biopsy core involvement is not associated with an increased risk of cancer recurrence following 5-fraction stereotactic body radiation therapy monotherapy
Jonathan W Lischalk, Astrid Sanchez, Vianca F Santos, et al.
Urology
|
December 11, 2003
Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer
Yoshio Naya, Herbert A Fritsche, Carol D Cheli, et al.
Urology
|
October 18, 2002
Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter
Wolfgang Horninger, Carol D Cheli, Richard J Babaian, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 28, 2017
Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202
Amin J Mirhadi, Qiang Zhang, Gerald E Hanks, et al.
The New England Journal of Medicine
|
March 25, 2026
A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Ann Marie Navar, Elina Mikhailova, Alberico L Catapano, et al.
Urology
|
October 18, 2002
Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?
Yoshio Naya, Thomas A Stamey, Carol D Cheli, et al.
Page
of 46